DOCSLIB.ORG

Poisons Act 1957 01.01.2013.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Poisons Act 1957 01.01.2013.Pdf Singapore Statutes Online - 1 - Poisons Rules Page 1 of 125 Poisons Rules 1 Citation 2 Definitions 3 Licences 4 Form of record of sales 5 Wholesale sales 6 (Deleted) 7 (Deleted) 8 Fees 9 Extension of labelling provisions 10 Limitation of section 6 (3) of Act to certain substances 11 Extension of section 6 (3) to section 8 of Act, sales and supply by commercial sample, and relaxation of this subsection 12 Relaxation of section 7 (3) of Act in case of certain medicines 13 Exemption from provisions relating solely to substances in First Schedule 14 Complete exemption of certain articles and poisons 14A Exemption for retail sale of poisons by pharmacists 14B (Deleted) 14C (Deleted) 15 Additional restrictions on sale of certain poisons 16 Coded prescription prohibited 17 Restrictions on sale of codeine cough preparations by pharmacists 18 Restriction of sale of strychnine 19 Manner of labelling containers 20 Labelling of name of poison 21 Labelling of particulars as to proportion of poison 22 Indication of character of poison 23 Special cautions in case of certain substances 24 Relaxation of certain labelling requirements 25 Form of containers 26 Storage of poisons 27 Transport of poisons 28 Special provisions with respect to transport of certain poisons 29 Supply of medicines to outpatients from certain hospitals, etc. 30 Supply of medicines for use in hospitals, etc. 31 Storage of poisons in institutions 32 Manufacture of pharmaceutical preparations 33 Colouring of poisons 34 Preservation of records 35 Penalties FIRST SCHEDULE Substances falling within the Poisons List to which special restrictions under rule 10 apply http://statutes.agc.gov.sg/aol/search/display/printView.w3p;page=0;query=Id%3A%2... 05/03/2015 Singapore Statutes Online - 1 - Poisons Rules Page 2 of 125 SECOND SCHEDULE Articles exempted under rule 14 from the provisions of the Act and the rules made thereunderGroup IGeneral Exemptions THIRD SCHEDULE Substances required by rule 15 to be sold upon a prescription given by a medical practitioner, dentist or veterinary surgeons FOURTH SCHEDULE Statement of particulars as to the proportion of poison in certain cases permitted by rule 21(2) FIFTH SCHEDULE Indication of character of article prescribed by rule 22 for the purposes of section 6(2)(c) of the Act SIXTH SCHEDULE Substances to which rule 28 (Transport) applies SEVENTH SCHEDULE Substances to which rule 33 (Colouring) applies EIGHTH SCHEDULE NINTH SCHEDULE Fees TENTH SCHEDULE Labelling prescribed by rules 22 and 23 ELEVENTH SCHEDULE TWELFTH SCHEDULE THIRTEENTH SCHEDULE Legislative History POISONS ACT (CHAPTER 234, SECTION 20(1)) POISONS RULES R 1 G.N. No. S 94/1957 REVISED EDITION 1999 (1st January 1999) [5th April 1957] Citation 1. These Rules may be cited as the Poisons Rules. Definitions 2.—(1) In these Rules, unless the context otherwise requires — “animal” includes poultry; “antimonial poisons” means chlorides of antimony, oxides of antimony, sulphides of antimony, antimonates, antimonites and organic compounds of antimony; “arsenical poisons” means halides of arsenic, oxides of arsenic, sulphides of arsenic, arsenates, arsenites, copper aceto- arsenites, sodium thioarsenates and organic compounds of arsenic; http://statutes.agc.gov.sg/aol/search/display/printView.w3p;page=0;query=Id%3A%2... 05/03/2015 Singapore Statutes Online - 1 - Poisons Rules Page 3 of 125 “British Pharmacopoeia” and “Pharmaceutical Codex” include the supplements and addenda thereto; “Chinese proprietary medicine” has the same meaning as in the Medicines (Traditional Medicines, Homoeopathic Medicines and other Substances) (Exemption) Order (Cap. 176, O 6); [S 714/2012 wef 01/01/2013] “codeine cough preparation” means any medicine in liquid form that contains codeine and is intended for the treatment of coughs; “food” includes a beverage; “licensed importer” means an importer licensed under the Act; “licensed person” means a person licensed under the Act; “medical device” means a medical device referred to in the First Schedule to the Health Products Act (Cap. 122D); [S 714/2012 wef 01/01/2013] “mercurial poisons” means oxides of mercury, mercuric salts and organic compounds of mercury; “registered nurse” means a nurse whose name is included in any part of the register of nurses maintained under the Nurses and Midwives Act (Cap. 209); “registered pharmacy” means a pharmacy registered under section 37 of the Medicines Act (Cap. 176); “sale by wholesale” means sale in any of the circumstances set out in section 8 of the Act; [S 539/2008 wef 01/11/2008] “sell by retail”, in relation to any poison, means to sell the poison otherwise than by wholesale. (2) In these Rules — (a) any reference to an alkaloid shall include a reference to any salt of that alkaloid and in a case where the esters of an alkaloid are included in the Poisons List by virtue of the words, “its esters”, to any ester of that alkaloid; and (b) any reference to medicines for the internal treatment of human ailments shall include any medicine to be administered by hypodermic injection but shall not include a reference to gargles, mouth-washes, eye-drops, eye-lotions, ear-drops, preparations for naso-pharyngeal use, and douches for rectal, vaginal or urethral use. (3) Any reference in the Schedules to the percentage of a poison contained in any substance shall, unless otherwise expressly provided, be construed in the following manner, that is to say, a reference to a substance containing 1% of any poison means: (a) in the case of a solid, that one gramme of the poison is contained in every 100 grammes of the substance; and (b) http://statutes.agc.gov.sg/aol/search/display/printView.w3p;page=0;query=Id%3A%2... 05/03/2015 Singapore Statutes Online - 1 - Poisons Rules Page 4 of 125 in the case of a liquid, that one millilitre of the poison, or, if the poison itself is a solid, one gramme of the poison, is contained in every 100 millilitres of the substance, and so in proportion for any greater or lesser percentage. Licences 3.—(1) A licence to import, store and sell by wholesale poisons included in the Poisons List shall be in Form A of the Eighth Schedule. (2) A licence to import and deal generally in poisons by wholesale and retail shall be in Form C set out in the Eighth Schedule. Form of record of sales 4. The particulars of sales of poisons which are required by section 6 (3) (b) of the Act to be entered in a book shall be entered in Form D set out in the Eighth Schedule. Wholesale sales 5.—(1) [Deleted by S 177/99 wef 01/04/1999] (2) A person so licensed shall keep a record of the arrival and sale of poisons in a book or other form of record kept solely for that purpose but shall not be required to comply with section 6 (3) (b) of the Act. (3) The record shall be kept in Form E set out in the Eighth Schedule or otherwise recorded in such manner as to provide all the particulars required in that Form. (4) A person so licensed shall obtain an order in writing in accordance with rule 10 in respect of the sale of any poison and shall enter a reference to such order in the record kept in pursuance of paragraph (2). 6. [Deleted by S 177/99 wef 01/04/1999] 7. [Deleted by S 177/99 wef 01/04/1999] Fees 8. The fees for licences under the Act shall be as set out in the Ninth Schedule. Extension of labelling provisions 9. The provisions of section 6(2) of the Act and the provisions of these Rules relating to the labelling of poisons — (a) shall apply to the sale of any poison in the circumstances set out in section 8 (a), (c), (d), (e), (f) and (g) of the Act; and (b) shall also apply with respect to the supply of poisons (otherwise than by sale) in like manner as if references in those provisions to the sale and seller of poisons included references to the supply and supplier of poisons, respectively. Limitation of section 6 (3) of Act to certain substances http://statutes.agc.gov.sg/aol/search/display/printView.w3p;page=0;query=Id%3A%2... 05/03/2015 Singapore Statutes Online - 1 - Poisons Rules Page 5 of 125 10. Except as provided in section 8 of the Act, section 6(3) of the Act shall apply to all substances in the First Schedule (whether or not they consist of or contain poisons included in the Poisons List) and which are not specified in the Fifth Schedule. [S 177/99 wef 01/04/1999] Extension of section 6 (3) to section 8 of Act, sales and supply by commercial sample, and relaxation of this subsection 11.—(1) Section 6(3) of the Act as modified by rule 10 — (a) shall apply to sales exempted by section 8 of the Act except sales of poisons to be exported from Singapore to a place other than Malaysia; and (b) shall also apply to the supply in the form of commercial sample, otherwise than on sale, of any substance included in the First Schedule in like manner as if references to the sale and seller of poisons respectively included references to the supply and supplier of poisons in the form of commercial samples. (2) So much of section 6(3) of the Act as requires an entry in a book to be signed by the purchaser of a poison shall not, as respects the sale of a poison to a person for the purpose of his trade, business or profession, apply if the following requirements are satisfied: (a) the seller obtains before the completion of the sale an order in writing signed by the purchaser stating his name and address, trade, business or profession, and the following particulars in regard to the article to be purchased, that is to say, the purpose for which it is required and the total quantity to be purchased, or, in the case of an article packed in ampoules, either the total quantity to be purchased or the total quantity intended to be administered or injected; (b) the seller is satisfied that the signature is that of the person purporting to have signed the order, that the person carries on the trade, business or profession stated in the order, and that it is one in which the poison to be purchased is used; and (c) the seller inserts in the appropriate entry in the record prescribed by rule 4 or 5 the words, “signed order” and a reference number by which the order can be identified.
Load more

Recommended publications
  • (Mdma) in Non Conventional Matrices and Its Applications in Clinical Toxicology
    Doctoral Thesis Doctorat Farmacología Departament de Farmacología, de Terapéutica i de Toxicologia DISTRIBUTION OF 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) IN NON CONVENTIONAL MATRICES AND ITS APPLICATIONS IN CLINICAL TOXICOLOGY SIMONA PICHINI p Doctoral Thesis Doctorat Farmacología Departament de Farmacología, de Terapéutica i de Toxicologia DISTRIBUTION OF 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) IN NON CONVENTIONAL MATRICES AND ITS APPLICATIONS IN CLINICAL TOXICOLOGY Doctoral thesis submitted by Simona Pichini as a partial fulfillment of the requirements for the degree of Doctor by the Universitat Autònoma de Barcelona. The studies included in this thesis have been realized under the direction of Dr. Rafael de la Torre Fornell and Dr. Magí Farré Albaladejo at the Pharmacology Unit of the Institut Municipal d'Investigació Mèdica (IMIM), Barcelona, Spain; and at the Drug Research and Control Department of the Istituto Superiore di Sanità, Roma, Italy. Doctorate Program of the Universitat Autònoma de Barcelona. Signature of Thesis Director Signature of Thesis Director (Dr. Magí Farré Albaladejo) (Dr. Rafael de la Torre Fornell) Signature of Doctorand (Simona Pichini) Yo soy yo y aquéllos a quienes amo Jorge Bucay To my friends, treasure of my life Acknowledgements Acknowledgements A number of people contributed to high extent to achieve the objectives of this Doctoral Thesis prepared between the two cities of Rome and Barcelona. This means that there are many people I’d the opportunity to meet, to work with, to share wonderful and terrible moments, and that I’d like to thank in these pages. First of all, to Dr. Piergiorgio Zuccaro, my “creator”, who always believed in me, supported my job and hardly fought to give me all the possible opportunities to grow up as an investigator; To Dr.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • A Randomized Double-Blind, Double-Dummy
    pISSN 1598-2998, eISSN 2005-9256 Cancer Res Treat. 2014;46(1):19-26 http://dx.doi.org/10.4143/crt.2014.46.1.19 Original Article Open Access A Randomized Double-Blind, Double-Dummy, Multicenter Trial of Azasetron versus Ondansetron to Evaluate Efficacy and Safety in the Prevention of Delayed Nausea and Vomiting Induced by Chemotherapy Hee Yeon Lee, MD 1 Purpose Hoon-Kyo Kim, MD 1 This study was conducted to evaluate the efficacy and safety of azasetron compared Kyung Hee Lee, MD 2 to ondansetron in the prevention of delayed chemotherapy-induced nausea and Bong-Seog Kim, MD 3 vomiting. MD 4 Hong Suk Song, Materials and Methods MD 5 Sung Hyun Yang, This study was a multi-center, prospective, randomized, double-dummy, double-blind MD 6 Joon Hee Kim, and parallel-group trial involving 12 institutions in Korea between May 2005 and MD 7 Yeul Hong Kim, December 2005. A total of 265 patients with moderately and highly emetogenic MD 8 Jong Gwang Kim, chemotherapy were included and randomly assigned to either the azasetron or MD 9 Sang-We Kim, ondansetron group. All patients received azasetron (10 mg intravenously) and MD 10 Dong-Wan Kim, dexamethasone (20 mg intravenously) on day 1 and dexamethasone (4 mg orally every MD 11 Si-Young Kim, 12 hours) on days 2-4. The azasetron group received azasetron (10 mg orally) with MD 12 Hee Sook Park, placebo of ondansetron (orally every 12 hours), and the ondansetron group received Department of Internal Medicine, ondansetron (8 mg orally every 12 hours) with placebo of azasetron (orally) on days 1St.
    [Show full text]
  • Poisons Act.Fm
    LAWS OF BRUNEI CHAPTER 114 POISONS Enactment No. 13 of 1956 Amended by S 103/1958 Enactment No. 6 of 1967 S 101/1979 1984 Edition, Chapter 114 Amended by S 16/1996 S 28/2001 GN 273/2002 REVISED EDITION 2015 B.L.R.O. 1/2015 LAWS OF BRUNEI Poisons CAP. 114 1 LAWS OF BRUNEI REVISED EDITION 2015 CHAPTER 114 POISONS ARRANGEMENT OF SECTIONS Section 1. Citation. 2. Interpretation. 3. Description of poisons. 4. Licensing Officers. 5. General prohibition with respect to importation and sale of poisons. 6. Prohibitions and provisions relating to sale of poisons. 7. Exemptions in respect of medicines. 8. Exemptions in respect of sale. 9. Possession of poisons. 10. Issue of licences. 11. Different kinds of licence. 12. Licences to be numbered and registered. 13. Annual list to be published. 14. Forms of licence. 15. Search and search warrants. 16. Powers of exemption. 17. Penalties. B.L.R.O. 1/2015 LAWS OF BRUNEI 2 CAP. 114 Poisons 18. Jurisdiction. 19. Prosecutions. 20. Prohibition of sale to persons under 18. 21. Rules. SCHEDULE — POISONS LIST ____________________________ LAWS OF BRUNEI Poisons CAP. 114 3 POISONS ACT An Act to regulate the importation, possession, manufacture, compounding, storage, transport and sale of poisons Commencement: 1st January 1983 [S 61/1957] Citation. 1. This Act may be cited as the Poisons Act. Interpretation. 2. In this Act, unless the context otherwise requires — “dentist” means a dentist licensed under the Medical Practitioners and Dentists Act (Chapter 112) and includes a Government dentist; “export”, in relation
    [Show full text]
  • University of Groningen Multi-Residue Analysis of Growth Promotors In
    University of Groningen Multi-residue analysis of growth promotors in food-producing animals Koole, Anneke IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 1998 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Koole, A. (1998). Multi-residue analysis of growth promotors in food-producing animals. s.n. Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 25-09-2021 APPENDIX 1 OVERVIEW OF RELEVANT SUBSTANCES This appendix consists of two parts. First, substances that are relevant for the research presented in this thesis are given. For each substance CAS number (CAS), molecular weight (MW), bruto formula (formula) and if available UV maxima and alternative names are given. In addition, pKa values for the ß-agonists are listed, if they were available.
    [Show full text]
  • Modified Release
    Product list Modified Release Our product list consist of the pharmaceuticals, pharmaceutical associations and food in the dosages and forms most required by our customers (please check www.osmopharm.com for more details). Our Research and Development competencies are assuring the flexibility in developing new formulations and forms of the products in list as well as new ones. PRODUCTS RELEASE BULK FORM DOSAGE FINAL FORM THERAPEUTICITY A Acetazolamide SR Pellets 500 mg caps Diuretic Alfacalcidol IR Pellets 1 μg caps Vit D supplement Alfuzosin Hydrochloride SR Powder 2.5 mg – 10 mg tabs Prostatic Hypertrophy agent Allopurinol SR Pellets 300 mg caps Antiurolytic Alprazolam SR Pellets 1 mg caps Anxiolytic Ambroxol HCI SR Pellets 75 mg, 120 mg caps Expectorant Ambroxol HCI SR Resinates 75 mg, 120 mg caps / tabs Expectorant Amitriptyline SR Pellets 25 mg, 50 mg, 75 mg caps Antidepressant Aspirin EC, IR Pellets 100 mg caps Anticoagulant Aspirin EC, IR Microcapsules 100 mg caps / tabs Anticoagulant Atenolol IR Pellets 50 mg caps Antihypertensive Azithromycin IR Pellets 250 mg caps Antibiotic B B-complex Benproperine IR Resinates 25 mg, 50 mg caps / tabs Antitussive Betahistine 2HCI SR Pellets 12 mg, 24 mg, 48 mg caps Vasodilator Bromopride* SR Pellets 20 mg caps Antiemetic Brompheniramine maleate SR Pellets 6 mg, 8 mg, 12 mg caps Antihistaminic C Caffeine SR, IR Pellets 25 mg, 50 mg, 300 mg caps CNS Stimulant Carbetapentane citrate SR Pellets 75 mg caps Antitussive Carbinoxamine maleate SR Pellets 4mg, 6 mg caps Antihistaminic Carbinoxamine
    [Show full text]
  • Download Product Insert (PDF)
    PRODUCT INFORMATION Azasetron (hydrochloride) Item No. 28383 CAS Registry No.: 123040-16-4 Formal Name: N-1-azabicyclo[2.2.2]oct-3-yl-6-chloro-3,4- dihydro-4-methyl-3-oxo-2H-1,4-benzoxazine- Cl N 8-carboxamide, monohydrochloride O Synonym: Y-25130 MF: C H ClN O • HCl N 17 20 3 3 O FW: 386.3 Purity: ≥98% • HCl N O UV/Vis.: λmax: 221, 307 nm Supplied as: A crystalline solid H Storage: -20°C Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Description Azasetron is an orally bioavailable antagonist of the serotonin (5-HT) receptor subtype 5-HT3 1,2 (Ki = 2.9 nM). It is selective for 5-HT3 over 5-HT1A and 5-HT2 (IC50 = >10 μM for both), as well as dopamine D1 and D2 and α1- and α2-adrenergic receptors (IC50s = >10 μM), but it does bind to histamine H1 receptors (IC50 = 4.4 μM). Azasetron inhibits contractions induced by 5-HT (Item No. 14332) in isolated guinea pig ileum (pA2 = 7.04) and isolated rabbit heart (pA2 = 10.06). It inhibits emesis induced by cisplatin (Item No. 13119) in dogs and induced by doxorubicin (Item No. 15007) combined with cyclophosphamide (Item No. 13849) in ferrets when administered at a dose of 1 mg/kg.1 References 1. Haga, K., Inaba, K., Shoji, H., et al. The effects of orally administered Y-25130, a selective serotonin3-receptor antagonist, on chemotherapeutic agent-induced emesis. Jpn. J. Pharmacol. 63(3), 377-383 (1993).
    [Show full text]
  • Pdf 36.06 Kb
    PROJECT REVIEW “Synthesis and Characterisation of Metabolites for the Integration in a Comprehensive Screening Procedure utilizing LC-MS/MS” W. Schänzer, M. Parr (German Sport University, Cologne, Germany) In the fight against doping the laboratories are confronted with an increasing number of substances to screen on. Therefore new methods have to be implemented by the laboratories. To keep the costs for doping control analysis acceptable, to ensure rapid reporting times and to lower the amount of urine needed to screen for all substances, a comprehensive screening for different classes of substances is desirable. Following the 2005 application WADA has granted a pilot project to check for the applicability of direct LC-MS/MS measurement of sulfoconjugates of heavy volatile stimulants. As most of the beta-2 agonists and heavy volatilestimulants are conjugated to sulfuric acid in humans an extension of the method to other compounds is desirable. As reference substances of the conjugates are barely available, during the pilot project the sulfoconjugates of p-Hydroxyamphetamine, p-Hydroxymetamphetamine (Pholedrine), p- Hydroxyephedrine, p-Hydroxynorephedrine, Etilefrine and Etamivan were synthesized by coupling the aglycons to sulfuric acid by reaction with sulfur trioxide pyridine complex. The objective of the continuation is to extend the combined screening procedure for diuretics and heavy volatile stimulants developed in the pilot project to other compounds. Thus, studies on the metabolism have to be reviewed and relevant metabolites have to be synthesised. The structures of all relevant products will be confirmed by nuclear magnetic resonance. For the integration in a comprehensive screening procedure the analytes will be characterised by means of LC-MS/MS.
    [Show full text]
  • Simultaneous Determination of Dexamethasone, Ondansetron, Granisetron, Tropisetron, and Azasetron in Infusion Samples by HPLC with DAD Detection
    Hindawi Publishing Corporation Journal of Analytical Methods in Chemistry Volume 2017, Article ID 6749087, 7 pages http://dx.doi.org/10.1155/2017/6749087 Research Article Simultaneous Determination of Dexamethasone, Ondansetron, Granisetron, Tropisetron, and Azasetron in Infusion Samples by HPLC with DAD Detection Fu-chao Chen,1 Lin-hai Wang,2 Jun Guo,3 Xiao-ya Shi,1 and Bao-xia Fang1 1 Department of Pharmacy, Dongfeng Hospital, Hubei University of Medicine, Shiyan, Hubei 442008, China 2Department of Pharmacy, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, China 3Department of Oncology, Dongfeng Hospital, Hubei University of Medicine, Shiyan, Hubei 442008, China Correspondence should be addressed to Bao-xia Fang; [email protected] Received 21 October 2016; Accepted 19 December 2016; Published 11 January 2017 Academic Editor: Chih-Ching Huang Copyright © 2017 Fu-chao Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. A simple and rapid high-performance liquid chromatography with diode array detector (HPLC-DAD) method has been developed and validated for simultaneous quantification of five antiemetic agents in infusion samples: dexamethasone, ondansetron, granisetron, tropisetron, and azasetron. The chromatographic separation was achieved on a Phenomenex18 C column (4.6 mm × 150 mm, 5 m) using acetonitrile-50 mM KH2PO4 buffer-triethylamine (25 : 74 : 1; v/v; pH 4.0). Flow rate was 1.0 mL/min witha ∘ column temperature of 30 C. Validation of the method was made in terms of specificity, linearity, accuracy, and intra- and interday precision, as well as quantification and detection limits.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Journal of Addiction and Dependence
    Journal of Addiction and Dependence www.ommegaonline.org Review Article Molecular Mechanisms of Drug Abuse, Dependency and Craving Richard E. Wilcox1*, Joseph D. Miller2 1Division of Pharmacology and Toxicology, College of Pharmacy, The University of Texas at Austin, Austin TX 78712, USA 2Department of Pharmacology, American University of the Caribbean School of Medicine, Cupecoy, St. Maarten *Corresponding author: Richard E. Wilcox, Ph.D, Professor of Neuropharmacology, University of Texas, College of Pharmacy 2409, University Avenue STOP A1900 Austin, TX 78712-1113; Tel: +(512) 471-5199; E-mail: [email protected] Abstract Received Date: November 4, 2015 Drug abuse and dependence are major medical, social, and economic prob- Accepted Date: December 30, 2015 lems for the world. Whereas the means to reduce abuse are well known, drug de- Published Date: January 5, 2016 pendency is a complex medical disease and current treatments attempt to reduce or prevent drug craving in dependent people as part of therapy. With the increased under- Citation: Wilcox, R.E., et al. Molecular standing of the neural mechanisms of drug dependence and the availability of several Mechanisms of Drug Abuse, Dependen- drugs that can treat craving in certain drug dependent populations it is important to cy and Craving. (2016) J Addict Depend summarize development of anti-craving therapeutics world-wide. The present paper 2(1): 40- 51. briefly outlines the problems of drug abuse and dependence, key aspects of the drug dependence process, the nature and mechanisms of drug craving in dependent people, current drug dependence theories, and finally mechanisms of action of anti-craving agents.
    [Show full text]